ELVN Form 144 Filed — Founder Sells 25,000 Shares; 12,500 Proposed Sale

Rhea-AI Filing Summary

Form 144 notice filed for Enliven Therapeutics (ELVN) by a holder reporting proposed and recent sales of common stock. The filer indicates a proposed sale of 12,500 shares through Jefferies LLC with an aggregate market value of $230,375.00, and reports that the shares were originally acquired as founder shares on 09/01/2019 from Enliven Therapeutics. The filing also discloses sales by the same person totaling 25,000 shares during the past three months, producing gross proceeds of $531,767.21. The issuer has 59,000,000 shares outstanding and the proposed sale is scheduled approximately for 09/17/2025. The filer certifies no undisclosed material adverse information and includes standard Rule 144 representations.

Positive

• Disclosure compliance: The filer provides complete Rule 144 fields including acquisition date, nature of acquisition, broker, and amounts, which aids investor transparency
• Detailed recent sale data: Recent three-month sales include dates, share amounts and gross proceeds allowing clear tracking of insider transactions

Negative

• Insider selling activity: Combined recent sales total 25,000 shares with gross proceeds of $531,767.21, and a proposed additional sale of 12,500 shares, which may be interpreted negatively by some investors
• Limited context: Filing does not state whether sales are part of a Rule 10b5-1 plan or personal liquidity needs, leaving motives unclear

Insights

Securities Analyst

TL;DR: Insider sales disclosed but represent a very small fraction of outstanding shares; monitoring useful for liquidity context.

The filing reports both a proposed sale and multiple recent dispositions by an insider or founder totaling 37,500 shares when combining the proposed sale (12,500) and prior three-month sales (25,000). The recent sales generated aggregate gross proceeds of $531,767.21, and the pending trade is valued at $230,375.00. Compared with the issuer's 59,000,000 outstanding shares, these amounts are immaterial to capitalization, suggesting limited direct impact on share supply or valuation. The disclosure is routine compliance with Rule 144 and provides clear dates, counterparties and acquisition history; there is no earnings or operational data in the filing to alter fundamentals.

Corporate Governance Expert

TL;DR: Documentation follows Rule 144 standards; signatures and 10b5-1 status are noted but not detailed.

The Form 144 includes the required details: class of security, broker name, acquisition date and nature (Founder Shares acquired 09/01/2019), and exact sale amounts and proceeds for recent trades. The filer affirms no undisclosed material adverse information and references Rule 10b5-1 plan adoption fields, though no plan adoption date is provided. From a governance perspective the submission is compliant but offers no additional context on whether the sales reflect personal liquidity needs, planned diversification, or trading-plan activity.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	12500	230375.00	59000000	09/17/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2019	Founder Shares	Enliven Therapeutics			12500	09/01/2019	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	07/17/2025	12500	281517.75
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	08/18/2025	10393	208106.00
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	08/19/2025	590	11800.00
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	08/20/2025	1517	30343.46

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the Form 144 filed for Enliven Therapeutics (ELVN) disclose?

The form discloses a proposed sale of 12,500 common shares via Jefferies with an aggregate market value of $230,375.00 and recent sales of 25,000 shares in the past three months generating $531,767.21 in gross proceeds.

Who acquired the shares and when were they acquired?

The shares to be sold were acquired as Founder Shares from Enliven Therapeutics on 09/01/2019.

When is the proposed sale scheduled and through which broker?

The approximate date of the proposed sale is 09/17/2025 and the broker listed is Jefferies LLC.

How many shares does Enliven Therapeutics have outstanding according to the filing?

The filing lists 59,000,000 shares outstanding.

Did the filer state whether a Rule 10b5-1 plan applies?

The form includes the field for plan adoption or instruction date but no plan adoption date is provided in the filing.